Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen

Completed

Conditions studied: HIV Infection

In brief

The hypothesis of this study is that the level of adherence necessary to achieve HIV virologic suppression with a ritonavir boosted protease inhibitor regimen (i.e. lopinavir/ritonavir) is less than the 95% rate observed in the published literature with unboosted regimens.

Key facts

Study ID

NCT00200369

Run by

Montefiore Medical Center

People needed

90

Starts

2004-05-01

Expected to finish

2006-03-01

Last updated by the study team

2009-11-05

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• HIV infection
• Receiving twice daily Kaletra at an FDA approved dosage
• Age>18 years
• CD4 and viral load available within seven day of enrollment
• Patient willingness to accept MEMS cap monitoring
• HIV genotype within 60 days of enrollment for patients with viral load>1000
• Patient willingness to grant informed consent and complete five study visits

You may not qualify if…

• Provider or patient deem it unlikely that Kaletra therapy will continue for the ensuing 24 weeks
• Prescription of any medication that is contraindicated for Kaletra recipients

Where it is running

• Montefiore Medical Center I.D. Clinic — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.